(Q40114855)

17 September 2017

1 reference

title

Dopamine autoreceptor stimulation: clinical significance (English)

1 reference

17 September 2017

Dopamine autoreceptor stimulation: Clinical significance (English)

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

1 September 2023

0 references

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

1 September 2023

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

1 September 2023

author name string

H. Y. Meltzer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6223322

1 September 2023

language of work or name

English

0 references

publication date

1 January 1982

1 reference

full work available at URL

17 September 2017

https://api.elsevier.com/content/article/PII:0091305782905044?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

https://api.elsevier.com/content/article/PII:0091305782905044?httpAccept=text/plain

1 September 2023

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Pharmacology, Biochemistry and Behavior

1 September 2023

published in

1 reference

17 September 2017

17 Suppl 1

1 reference

17 September 2017

1-10

1 reference

Dopamine ?Autoreceptors?: Pharmacological characterization by microiontophoretic single cell recording studies

17 September 2017

2

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Restatement and Prospectives of Ergot Alkaloids in Clinical Neurology and Psychiatry

1 September 2023

3

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Physiological significance of dopamine autoreceptors as studied following their selective blockade by molindone

1 September 2023

5

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Behavioral and neuroendocrine effects of low dose ET-495: Antagonism by haloperidol

1 September 2023

6

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Dopamine autoreceptor subsensitivity: a mechanism common to the treatment of depression and the induction of amphetamine psychosis

1 September 2023

7

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Stereoselectivity of presynaptic autoreceptors modulating dopamine release

1 September 2023

8

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Antipsychotic Drug Action in Schizophrenic Patients: Effect on Cortical Dopamine Metabolism After Long-Term Treatment

1 September 2023

10

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Unique response to antipsychotic drugs is due to absence of terminal autoreceptors in mesocortical dopamine neurones.

1 September 2023

12

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Adverse clinical side effects of levodopa therapy

1 September 2023

13

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Dopamine receptors and sleep induction in man

1 September 2023

14

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Brom-ergocryptine in the Treatment of Phenothiazine-Induced Galactorrhoea

1 September 2023

15

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Cerebral glucography with positron tomography. Use in normal subjects and in patients with schizophrenia

1 September 2023

16

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Biogenic amine metabolism in tourette syndrome

1 September 2023

19

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN.

1 September 2023

21

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Paradoxical response to dopamine agonists in tardive dyskinesia

1 September 2023

22

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Parkinson Disease Treated With a Suspected Dopamine Receptor Agonist

1 September 2023

24

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Dopaminergic mechanisms in patients with extrapyramidal disease

1 September 2023

25

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Antagonistic effects of apomorphine and haloperidol on rat striatal synaptosomal tyrosine hydroxylase.

1 September 2023

26

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Bromocriptine in affective disorders. A pilot study

1 September 2023

28

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

1 September 2023

Q64864197

29

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Evidence for dopamine receptors in the human brain mediating sedation and sleep.

1 September 2023

31

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

THERAPEUTIC EFFICACY OF APOMORPHINE COMBINED WITH AN EXTRACEREBRAL INHIBITOR OF DOPAMINE RECEPTORS IN PARKINSON'S DISEASE

1 September 2023

32

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

A study of the changes in motor behaviour caused by TRH on intracerebral injection

1 September 2023

34

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Low-dose apomorphine reduces serum homovanillic acid concentrations in schizophrenic patients

1 September 2023

35

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Comparison of dopamine synthesis regulation in the terminals of nigrostriatal, mesolimbic, tuberoinfundibular and tuberohypophyseal neurons

1 September 2023

37

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Accumulation of L-dopa in the median eminence: an index of tuberoinfundibular dopaminergic nerve activity

1 September 2023

38

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Self-inhibitory dopamine receptors: their role in the biochemical and behavioral effects of low doses of apomorphine

1 September 2023

39

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Evidence for the existence of regulatory DA receptors in the substantia nigra

1 September 2023

40

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Destruction of post-synaptic dopamine receptors prevents neuroleptic-induced activation of striatal tyrosine hydroxylase but not dopamine synthesis stimulation

1 September 2023

41

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Stimulation of "regulatory" dopamine receptors by bromocriptine (CB-154).

1 September 2023

42

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Evidence for selective and long-lasting stimulation of “regulatory” dopamine-receptors by bromocriptine (CB 154)

1 September 2023

43

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Drug-induced changes in the release of 3 H-monoamines from field stimulated rat brain slices.

1 September 2023

44

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Effects of Dopamine Agonists and Antagonists in Tourette's Disease

1 September 2023

45

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

A note on apomorphine as a sedative

1 September 2023

46

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Feedback loop or output pathway in striato-nigral fibres?

1 September 2023

48

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

A dopaminergic mechanism in mania

1 September 2023

49

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Differential actions of dopamine agonists and antagonists on the gamma-butyrolactone-induced in mouse brain dopamine

1 September 2023

50

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

The Medical Treatment of Spasmodic Torticollis

1 September 2023

51

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Gilles de la Tourette's syndrome following methylphenidate administration.

1 September 2023

52

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Neurochemical and behavioral evidence for a selective presynaptic dopamine receptor agonist

1 September 2023

53

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

3-PPP, a new centrally acting DA-receptor agonist with selectivity for autoreceptors

1 September 2023

55

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Dopamine (3-hydroxytyramine) and brain function

1 September 2023

57

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia

1 September 2023

58

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Comparison of the effects of neuroleptic drugs on pre- and postsynaptic dopaminergic mechanisms in the rat striatum

1 September 2023

59

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Bromocriptine treatment of spasmodic torticollis. A double-blind crossover study

1 September 2023

60

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Apomorphine and psychopathology

1 September 2023

62

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Effect of apomorphine on growth hormone, prolactin, luteinizing hormone and follicle-stimulating hormone levels in human serum

1 September 2023

63

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Dopamine receptor mediated inhibition by pergolide of electrically-evoked 3H-dopamine release from striatal slices of cat and rat: Slight effect of ascorbate

1 September 2023

65

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

A Study of Growth Hormone Release in Depression

1 September 2023

66

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Pharmacological profiles of the putative dopamine autoreceptor agonists 3-PPP and TL-99.

1 September 2023

67

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Specific distribution of metabolic alterations in cerebral cortex following apomorphine administration

1 September 2023

68

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Pimozide: delayed onset of action at rat striatal pre- and postsynaptic dopamine receptors

1 September 2023

69

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Clinical evidence for multiple dopamine receptors in man

1 September 2023

70

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Relevance of Dopamine Autoreceptors for Psychiatry: Preclinical and Clinical Studies

1 September 2023

71

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

The dopamine hypothesis of schizophrenia: a review

1 September 2023

72

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Bromocriptine treatment of depressive disorders. Clinical and biochemical effects

1 September 2023

73

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Dopamine in substantia nigra and cortex after γ-butyrolactone treatment

1 September 2023

75

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Letter: Effects of low doses of a dopamine-receptor stimulator in mania

1 September 2023

76

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Repeated electroconvulsive shock prevents the sedative effect of small doses of apomorphine

1 September 2023

81

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Chronic treatment with antidepressants prevents the inhibitory effect of small doses of apomorphine on dopamine synthesis and motor activity

1 September 2023

82

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

The symptomatology and diagnosis of Gilles de la Tourette's syndrome

1 September 2023

83

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Dopamine Auto- and Postsynaptic Receptors: Electrophysiological Evidence for Differential Sensitivity to Dopamine Agonists

1 September 2023

84

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Effect of apomorphine on schizophrenic symptoms

1 September 2023

86

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

The role of brain dopamine in behavioral regulation and the actions of psychotropic drugs.

1 September 2023

87

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Effect of dopamine receptor agonists and antagonists on release of dopamine in the rabbit caudate nucleus in vitro

1 September 2023

88

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Supersensitivity of dopamine-autoreceptors. The effect of gammabutyrolactone in long-term haloperidol treated rats

1 September 2023

89

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Catecholamine receptor agonists: effects on motor activity and rate of tyrosine hydroxylation in mouse brain

1 September 2023

90

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Antagonism by haloperidol of locomotor depression induced by small doses of apomorphine

1 September 2023

91

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Involvement of both dopaminergic and alpha-adrenergic receptors in the hypomotility induced by dibenzoyl-6,7-ADTN

1 September 2023

92

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Behavioural and neurochemical studies on apomorphine-induced hypomotility in mice.

1 September 2023

93

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Presynaptic catecholamine antagonists as treatment for Tourette syndrome. Effects of alpha methyl para tyrosine and tetrabenazine.

1 September 2023

94

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Schizophrenic Symptoms Improve with Apomorphine

1 September 2023

95

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Treatment of schizophrenia with ergot derivatives

1 September 2023

97

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Levodopa in Huntington's chorea

1 September 2023

98

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Dopamine-synthesis and tyrosine-hydroxilase are regulated by independent DA-receptor mediated mechanisms

1 September 2023

104

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Subcellular localization of dopamine-sensitive adenylate cyclase and dopamine receptor binding activities

1 September 2023

105

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Midification of tardive dyskinesia and spasmodic torticollis by apomorphine. Possible role of dopamine autoreceptors

1 September 2023

107

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Apomorphine in Huntington's chorea: clinical observations and theoretical considerations

1 September 2023

108

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

The striatonigral fibres and the feedback control of dopamine metabolism

1 September 2023

109

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Injection of low doses of apomorphine into the nucleus accumbens of rats reduces locomotor activity

1 September 2023

110

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Haloperidol depresses the accumulation of apomorphine in the striatum of the rat

1 September 2023

111

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Bromocriptine and imipramine in endogenous depression. A double-blind controlled trial in out-patients

1 September 2023

112

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Dopaminergic neurons: An in vivo system for measuring drug interactions with presynaptic receptors

1 September 2023

113

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Do neuroleptics prevent the penetration of dopamine agonists into the brain?

1 September 2023

114

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

The role of presynaptic receptors in the release and synthesis of 3H-dopamine by slices of rat striatum

1 September 2023

115

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

Electrophysiological studies of neurons in the ventral tegmental area of Tsai

1 September 2023

116

1 reference

https://api.crossref.org/works/10.1016/0091-3057(82)90504-4

1 September 2023

Identifiers

1 reference

17 September 2017

1 reference